Summary Increasing interest has been focused on DNA ploidy, hormone receptor status and tumour size as prognostic factors in node-negative breast cancer. We analysed these factors in patients operated on for primary invasive breast cancer between January 1981 and December 1987 in a prospective study of 248 women with no involved axillary nodes and 188 women with positive nodes followed until 15 April 1989. Oestrogen or progesterone receptor negativity, aneuploidy and tumour diameter exceeding 20 mm were studied as negative prognostic signs in life table analyses and Cox proportional hazards models of corrected survival. Corrected survival decreased with increasing number of negative signs. Three to four signs yielded a statistically significant, two-to threefold higher risk than the others. Survival estimates by life table analyses differed by 20% at 5 years. In the whole group, women with three or four negative factors had a relative risk of dying from their disease more than twice that of the others. Women with no involved nodes and with three or four negative factors had a risk of dying from breast cancer similar to that of node-positive women with fewer than three.
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Adjuvant systemic therapy after primary surgery for breast cancer is of benefit to node-negative as well as node-positive patients (Early Breast Cancer Triallists' Collaborative Group, 1992) . The proportional reduction in recurrence and death with adjuvant treatment may be of an equal magnitude in both groups. A recommendation in a Clinical Alert from the National Cancer Institute (1988) to give adjuvant therapy to all node-negative patients has met with opposition because of the limited absolute gain and relatively common side-effects (DeVita, 1989; McGuire et al., 1989 McGuire et al., , 1990 . Therefore, there is growing interest in finding prognostic factors that can select women at high risk for distant metastases and death from node-negative breast cancer (McGuire et al., 1990) .
In studies of prognostic factors, there are methodological problems. The prognostic information associated with each factor is determined in mathematical models fitted to the investigators' own data and with few exceptions (Haybittle et al., 1982; Todd et al., 1987) not validated in other clinical settings. This strategy leads to an overestimation of the predictive value of the factors studied.
Furthermore, the prognostic factors under study have often been used as guidance for treatment within the studied cohort, which may confound the results. The results obtained from selected patient groups (Gelbfish et al., 1988) may not apply to a wider population.
We wanted to overcome these difficulties by applying a set of prognostic factors proposed by Sigurdsson et al. (1990) to a population-based series of breast cancer patients, treated according to a strict protocol not involving adjuvant systemic therapy. This model study was chosen as its setting is very similar to ours with respect to source population and standards of medical treatment. Measurement of the proposed prognostic factors is part of the standard examination of breast cancer tissue.
In our study there was no loss to follow-up. The analysis included both node-negative and node-positive patients to elucidate any difference in the predictive value of the prognostic factors.
Subjects and methods

Patients
We studied all patients from a period when we routinely sought full information on tumour diameter, axillary lymph 
Treatment
Mastectomy and axillary dissection were routine treatments at the beginning of the study period for cancers in stages I or II (UICC). Women with node-positive disease were treated with adjuvant radiotherapy applied to the axillary, supraclavicular and parasternal lymph nodes. Beginning in 1982, sector resection, with optional radiation of the remaining breast tissue, was introduced and recommended to most patients with unifocal tumours in stage I (Holmberg et al., 1990) . Adjuvant systemic therapy was not employed. In women with stage III or more advanced disease, the treatment was individualised.
Histopathological examination, hormone receptor assays and DNA measurements Tumour diameter was measured on the fresh specimen and the presence or absence of axillary lymph node metastases was noted.
Cytosol oestrogen receptor (ER) and progesterone receptor (PR) analyses were made by an isoelectric focusing technique (Wrange et al., 1978) . Tumour specimens were stored at -70°C for no more than 3 weeks before analysis. Receptor protein was expressed relative to DNA content, and when dichotomised into positive and negative a cut-off level of 0.1 fmol per ,ug of DNA was used.
The DNA content of tumour cells was analysed by flow cytometry or single-cell cytometry (Stang et al., 1985) . No distinction has been made between data acquired by the two methods. Statistical methods In the uni-and multivariate analyses of corrected survival rates, the Cox proportional hazards model was used. (Cox, 1972) . The basic model assumes that the hazard ('instantaneous death rate') h(t x) can be written: Figure 2 shows the life table estimates for four different subsets of patients: node-negative patients with two or fewer indicators vs those with three or more, and the corresponding subgrouping for the node-positive patients. The graphs shown for the node-negative patients with three or more poor prognostic indicators is very similar to the graph for the women with two or fewer indicators in the node-positive patient group. The difference between the life table estimates at 5 years for the two different groups of node-negative patients was 20% (95% confidence interval 9-31%).
Cox proportional hazards models Table III shows the results from multivariate models for prognosis, when patients were classified according to number of the factors hypothesised to be detrimental. In nodenegative patients, we found a relative hazard of 2 (95% confidence interval 1.9-2.1) for 2-3 risk factors present and a relative hazard of about 6 when four were present. However, none of the relative hazard estimates was statistically different from 1.
In a further model derived from data on all patients (Table  III) , women with negative nodes and none of the indicators present formed the reference group. In this model, the same pattern was seen with a statistically significant value (RH 6.4; 95% CI 1.5-3.3) for node-negative patients with four of the indicators present. In this model, a relative hazard of 3.4 was associated with node positivity, i.e. the RH of a node-positive woman is obtained by multiplying the risk estimate for any given number of risk factors in node-negative women by a factor of 3.4.
When node-negative patients were divided in two strata with 0-2 or 3-4 prognostic indicators present (Table IV) , the difference between the subgroups was clearly statistically significant at a relative hazard of 2.4 in a multivariate model. In a corresponding model utilising data on all patients (Table  IV) , the risk estimate with 3-4 indicators present was 2.9 for node-negative women and the relative hazard for nodepositive women was virtually unchanged (3.3) as compared with the previous models.
Results
The distribution of receptor status, aneuploidy and tumour diameter is displayed in Table I for both node-negative and node-positive patients. As expected, the mean tumour diameter, as well as the proportion of tumours exceeding 20mm, was larger among node-positive patients. The proportion of aneuploid tumours was slightly greater in the node-positive group.
The number and pecentages of women with none or up to four of the poor prognostic signs present are shown in Table  II . Of the node-negative patients 39.8% had three or more of the indicators of poor prognosis; the corresponding proportion among node-positive patients was 49.5%.
Life table analyses
Life table analysis on both node-negative and node-positive patients stratified according to the number of prognostic factors present is shown in Table II . There is a constantly worsening prognosis with increasing number of risk factors We also evaluated each one of the prognostic indicators separately (Table V) . In a model with node-negative patients only, the risk estimate for aneuploid tumours was the highest (RH = 6.2) and the only one statistically significant. In the model including all patients, the increased risks associated with both progesterone receptor negativity and a tumour diameter exceeding 20 mm were found to be statistically significant. The risk estimate for aneuploid tumours was smaller than in the first model but still statistically significant. The risk estimate for node positivity remained virtually the same as above.
In further analyses, interaction terms between nodal status and risk factors studied (individually or dichotomised as in Table III ) were formed. The estimates for the interaction terms were small and statistically far from significant. Thus, there was no indication that the prognostic information from these factors varied according to nodal status.
Risk index
Taking prognostic factors only as present or absent means that we assume that the risks associated with each factor are equal. As shown in Table V as Table II. The model, assuming the effect of all the four variables to be equal, is inferior to this index. However, the index is not a major improvement compared with the model shown in Table III . Using index 1, we obtain 16 different possible values, the largest being 2.62 when all risk factors are present (0.60 + 0.18 + 0.94 + 0.90). Having four risk factors thus implies a relative hazard of 13.7 compared with the most favourable group. A grouping based on quartiles of the index value (Table VI) confirms that this more complicated model is not markedly superior. The relative hazard of oestrogen receptor negativity (Table V) was not significantly different from 1. So, the index 1 model can be simplified by deleting this variable: Index 2 = 0.65 PR + 0.97 AU + 0.94 DI. This approach, which yields only eight possible values, is about equal to the index based on all four variables (Table  VI) .
Discussion
About one-third of the patients with stage I breast cancer in this study -with three or more negative prognostic factors present out of the four studied -have roughly the same prognosis as those doing best among node-positive women. These findings are similar to those obtained in our model study (Sigurdsson et al., 1990) and by others (Clark et al., 1989) . The prognostic factors were not different in node-positive and node-negative patients. One, therefore, might lose statistical power unecessarily by restricting prognostic studies to node-negative patients. (1992) . On the other hand, a group of women with few or no poor prognostic signs have a very good prognosis. Even if adjuvant systemic therapy were to be effective in those patients who would otherwise have a less favourable outcome, treating all patients with node-negative breast cancer seems to be of doubtful cost-effectiveness (Hillner & Smith, 1992) .
There are also both high-and low-risk patients among node-positive patients. However, in this 'low-risk' group the mere presence of axillary lymph node metastases implies a relative hazard of dying from breast cancer exceeding 3, confirming the theory that when axillary lymph node meta-stases have occurred the tumour has been present long enough to give rise to viable distant metastases in a large number of cases.
The event of axillary metastases may be seen as a function of tumour growth time. Tumour size reflects the same dimension. However, there were no signs of interaction between nodal status and receptor status or DNA ploidy. Receptor status and DNA ploidy can thus be interpreted to reflect a dimension of metastatic capacity independent of tumour burden, as well as of the time the tumour has been present. These factors might therefore be used in studies of whether early diagnosis has an impact on prognosis mainly by detection in a phase of less tumour burden and/or by capturing tumours of a less aggressive nature, as has been proposed (Duffy et al., 1992) .
This study provides further evidence that a high-risk group among node-negative patients can be distinguished by means of parameters that are today easily measured. It may also be that nuclear grading can replace the more cumbersome DNA measurements (Fisher et al., 1990) . It is, however, far from clear how these patients respond to systemic treatment. Randomised studies will evaluate whether chemotherapy or hormonal manipulation in an adjuvant setting in high-risk patients will be cost-effective. The question of malignancy progression during the early growth phase needs to be addressed in further studies on screening detected breast cancers.
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